Korean J Vet Res.  2011 Dec;51(4):253-257.

Pharmacokinetics of amikacin in plasma of healthy goats after intravenous injection once daily for three days

Affiliations
  • 1Division of Pharmacology and Toxicology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-J, R.S. Pura, Jammu-181 102 (J&K), India. shahidprawez@gmail.com
  • 2Division of Veterinary Pathology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-J, R.S. Pura, Jammu-181 102 (J&K), India.
  • 3Division of Pharmacology and Toxicology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir, Shuhama, Srinagar-190006, India.

Abstract

Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gram-negative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and noncompartmental open-model, respectively. The mean peak plasma concentrations (Mean +/- SD) of amikacin at time zero (Cp0) was 114.19 +/- 20.78 and 128.67 +/- 14.37 microg/mL, on day 1st and 3rd, respectively. The mean elimination half-life (t(1/2)ke) was 1.00 +/- 0.28 h on day 1st and 1.22 +/- 0.29 h on day 3rd. Mean of area under concentration-time curve (AUC(0-->infinity)) was 158.26 +/- 60.10 and 159.70 +/- 22.74 microg.h/mL, on day 1st and 3rd respectively. The total body clearance (ClB) and volume of distribution at steady state (Vdss) on day 1st and 3rd were ClB = 0.07 +/- 0.02 and 0.06 +/- 0.01 L/h.kg and Vdss = 0.10 +/- 0.03 and 0.11 +/- 0.05 L/kg, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokinetic-pharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens.

Keyword

amikacin; intravenous bolus injection; pharmacokinetics; three days; 10 mg/kg

MeSH Terms

Amikacin
Aminoglycosides
Body Weight
Goats
Gram-Positive Bacteria
Half-Life
Injections, Intravenous
Kanamycin
Plasma
Amikacin
Aminoglycosides
Kanamycin
Full Text Links
  • KJVR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr